A population-based study of cervical carcinoma and HPV infection in Latvia

被引:31
作者
Silins, I
Wang, XH
Tadesse, A
Jansen, KU
Schiller, JT
Avall-Lundqvist, E
Frankendal, B
Dillner, J [1 ]
机构
[1] MAS Univ Hosp, Dept Med Microbiol, S-20502 Malmo, Sweden
[2] Oncol Ctr Latvia, Riga, Latvia
[3] Karolinska Hosp, Radiumhemmet, Dept Gynecol Oncol, S-10401 Stockholm, Sweden
[4] Merck Sharp & Dohme Ltd, Res Labs, West Point, PA 19486 USA
[5] NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA
关键词
cervical cancer; epidemiology; HPV; infections; screening;
D O I
10.1016/j.ygyno.2004.01.044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. We wished to quantify the population-based importance of cervical carcinoma risk factors in Latvia. Methods. Totally, 223 of 224 eligible cases of incident invasive cervical carcinoma were enrolled during July 1998-February 2001 in Latvia. An age-matched sample of 300 healthy control women was selected from the Latvian population registry and 239 of these women (79%) were enrolled. A demographic and life-style questionnaire was completed, cervical brush samples were analyzed for human papillomavirus (HPV) DNA by PCR and serum samples for HPV antibodies. Results. Risk factors for cervical cancer in multivariate analysis were HPV type 16 or 18 DNA positivity (OR = 32.4; CI 95% 16.5-63.6) and living in the capital (OR = 2.4; Cl 95% 1.2-4.7). Oral contraceptive use was not a risk factor (OR = 0.4; CI 95% 0.2-1.1). A strong protective effect was found for having had more than three Pap smears in the last 5 years (OR = 0.07 CI 95% 0.03-0.19). Conclusions. Inadequate population coverage of Pap smears, in spite of excessive smear usage, caused 28.4% of cervical cancers in age groups eligible for screening. HPV type 16 infection was the most important risk factor for cervical cancer in Latvia, with a population-attributable risk percent for all ages of 58.5%. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:484 / 492
页数:9
相关论文
共 44 条
[1]  
af Geijersstam V, 1998, J INFECT DIS, V177, P1710, DOI 10.1086/517428
[2]   Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma [J].
Anttila, T ;
Saikku, P ;
Koskela, P ;
Bloigu, A ;
Dillner, J ;
Ikäheimo, I ;
Jellum, E ;
Lehtinen, M ;
Lenner, P ;
Hakulinen, T ;
Närvänen, A ;
Pukkala, E ;
Thoresen, S ;
Youngman, L ;
Paavonen, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (01) :47-51
[3]  
BERAL V, 1988, LANCET, V2, P1331
[4]  
BERRY G, 1993, INT J CANCER, V55, P228
[5]   Human papillomavirus in cervical cancer [J].
Bosch F.X. ;
Sanjosé S. .
Current Oncology Reports, 2002, 4 (2) :175-184
[6]   RISK-FACTORS FOR CERVICAL-CANCER IN COLOMBIA AND SPAIN [J].
BOSCH, FX ;
MUNOZ, N ;
DESANJOSE, S ;
IZARZUGAZA, I ;
GILI, M ;
VILADIU, P ;
TORMO, MJ ;
MOREO, P ;
ASCUNCE, N ;
GONZALEZ, LC ;
TAFUR, L ;
KALDOR, JM ;
GUERRERO, E ;
ARISTIZABAL, N ;
SANTAMARIA, M ;
DERUIZ, PA ;
SHAH, K .
INTERNATIONAL JOURNAL OF CANCER, 1992, 52 (05) :750-758
[7]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[8]   The causal relation between human papillomavirus and cervical cancer [J].
Bosch, FX ;
Lorincz, A ;
Muñoz, N ;
Meijer, CJLM ;
Shah, KV .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265
[9]  
BOYES DA, 1982, CLIN INVEST MED, V5, P1
[10]  
BRINTON LA, 1987, J NATL CANCER I, V79, P23